Completed PHASE3 INTERVENTIONAL 2-arm NCT00463346

Treatment With Acamprosate in Patients With Schizophrenia and Comorbid Alcoholism

Sponsor: Forest Laboratories

Conditions Alcohol Dependence Schizophrenia

Updated 6 times since 2017 Last updated: Mar 27, 2020 Started: Sep 30, 2006 Primary completion: Jul 31, 2015 Completion: Jul 31, 2015

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00463346, this PHASE3 trial focuses on Alcohol Dependence and Schizophrenia and remains completed. Sponsored by Forest Laboratories, it has been updated 6 times since 2006, reflecting limited change activity. Mental health research at this phase helps define safety and dosing parameters for future study.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Apr 2020 — Jan 2021 [monthly]

Completed PHASE3
Jun 2018 — Apr 2020 [monthly]

Completed PHASE3

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Completed PHASE3

First recorded

Sep 2006

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Forest Laboratories
Yale University

Data source: Yale University

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• West Haven, United States